BRPI0821676A2 - Composto, composição farmacêutica, e, processo para a preparação dos compostos. - Google Patents

Composto, composição farmacêutica, e, processo para a preparação dos compostos.

Info

Publication number
BRPI0821676A2
BRPI0821676A2 BRPI0821676-2A BRPI0821676A BRPI0821676A2 BR PI0821676 A2 BRPI0821676 A2 BR PI0821676A2 BR PI0821676 A BRPI0821676 A BR PI0821676A BR PI0821676 A2 BRPI0821676 A2 BR PI0821676A2
Authority
BR
Brazil
Prior art keywords
preparing
compounds
compound
pharmaceutical composition
pharmaceutical
Prior art date
Application number
BRPI0821676-2A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Neil James Hales
Alfred Arthur Rabow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0821676A2 publication Critical patent/BRPI0821676A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0821676-2A 2007-12-21 2008-12-18 Composto, composição farmacêutica, e, processo para a preparação dos compostos. BRPI0821676A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1575507P 2007-12-21 2007-12-21
US9609008P 2008-09-11 2008-09-11
US10780408P 2008-10-23 2008-10-23
PCT/GB2008/051206 WO2009081197A1 (en) 2007-12-21 2008-12-18 Bicyclic derivatives for use in the treatment of androgen receptor associated conditions

Publications (1)

Publication Number Publication Date
BRPI0821676A2 true BRPI0821676A2 (pt) 2015-06-16

Family

ID=40428336

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821676-2A BRPI0821676A2 (pt) 2007-12-21 2008-12-18 Composto, composição farmacêutica, e, processo para a preparação dos compostos.

Country Status (23)

Country Link
US (1) US8003649B2 (pt)
EP (1) EP2235010A1 (pt)
JP (1) JP2011507824A (pt)
KR (1) KR20100099742A (pt)
CN (1) CN101952286A (pt)
AR (1) AR069911A1 (pt)
AU (1) AU2008339572B2 (pt)
BR (1) BRPI0821676A2 (pt)
CA (1) CA2709514A1 (pt)
CL (1) CL2008003846A1 (pt)
CO (1) CO6331441A2 (pt)
CR (1) CR11524A (pt)
DO (1) DOP2010000195A (pt)
EA (1) EA017144B1 (pt)
EC (1) ECSP10010291A (pt)
IL (1) IL206284A0 (pt)
NI (1) NI201000110A (pt)
NZ (1) NZ586913A (pt)
PE (1) PE20091157A1 (pt)
TW (1) TW200927121A (pt)
UY (1) UY31559A1 (pt)
WO (1) WO2009081197A1 (pt)
ZA (1) ZA201004227B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013791A2 (en) * 2006-07-24 2008-01-31 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
BRPI0907844B8 (pt) 2008-02-22 2021-05-25 Radius Health Inc compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EA019320B1 (ru) 2008-12-22 2014-02-28 Мерк Патент Гмбх Новые полиморфные формы дигидрофосфата 6-(1-метил-1h-пиразол-4-ил)-2-{3-[5-(2-морфолин-4-илэтокси)пиримидин-2-ил]бензил}-2h-пиридазин-3-она и способы их получения
WO2010092371A1 (en) * 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
EP2430024A1 (en) * 2009-05-11 2012-03-21 AstraZeneca AB [1,2,4]triazolo [4,3-b]pyridazines as ligands of the androgen receptor
WO2011008543A2 (en) * 2009-06-29 2011-01-20 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
US8343977B2 (en) 2009-12-30 2013-01-01 Arqule, Inc. Substituted triazolo-pyrimidine compounds
JP5964756B2 (ja) 2010-02-04 2016-08-03 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
JP6376707B2 (ja) 2013-05-13 2018-08-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節剤としての置換架橋尿素類似体
EP3009424B1 (en) * 2013-06-10 2017-12-20 Astellas Pharma Inc. Bicyclic nitrogen-containing aromatic heterocyclic amide compound
NO2719005T3 (pt) * 2014-07-28 2018-01-20
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
WO2016161125A1 (en) * 2015-03-31 2016-10-06 University Of Vermont And State Agricultural College Methods for treating cryptosporidiosis using triazolopyridazines
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
CN110997670B (zh) * 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
GB201806663D0 (en) * 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
RS65638B1 (sr) 2018-11-14 2024-07-31 Janssen Pharmaceutica Nv Unapređene sintetičke metode pravljenja fuzionisanih heterocikličnih jedinjenja kao modulatora receptora oreksina
WO2020123670A1 (en) * 2018-12-11 2020-06-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof
CN109942574B (zh) * 2019-01-11 2022-04-01 成都阿奇生物医药科技有限公司 天奇替尼及其制备方法和用途
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN120097862A (zh) 2019-08-07 2025-06-06 詹森药业有限公司 制备作为食欲素受体调节剂的(2h-1,2,3-三唑-2-基)苯基化合物的改进的合成方法
US12152035B2 (en) 2020-12-30 2024-11-26 Industrial Technology Research Institute Androgen receptor binding molecule and use thereof
CA3218259A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators
AU2024376208A1 (en) * 2023-11-10 2026-04-30 Suven Life Sciences Limited Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
CN121181498A (zh) * 2025-09-03 2025-12-23 遵义医科大学第五附属(珠海)医院 一种醚类芳基哌嗪衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017163A1 (en) 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US7884104B2 (en) * 2004-10-01 2011-02-08 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2008109104A1 (en) * 2007-03-07 2008-09-12 The Regents Of The University Of California Bivalent inhibitors of akt protein kinase

Also Published As

Publication number Publication date
AR069911A1 (es) 2010-03-03
ECSP10010291A (es) 2010-07-30
KR20100099742A (ko) 2010-09-13
CO6331441A2 (es) 2011-10-20
NZ586913A (en) 2012-06-29
AU2008339572B2 (en) 2012-05-10
EP2235010A1 (en) 2010-10-06
CN101952286A (zh) 2011-01-19
US20100016279A1 (en) 2010-01-21
DOP2010000195A (es) 2010-08-31
JP2011507824A (ja) 2011-03-10
UY31559A1 (es) 2009-08-03
WO2009081197A1 (en) 2009-07-02
EA201000946A1 (ru) 2010-12-30
US8003649B2 (en) 2011-08-23
EA017144B1 (ru) 2012-10-30
TW200927121A (en) 2009-07-01
CR11524A (es) 2010-08-05
AU2008339572A1 (en) 2009-07-02
CA2709514A1 (en) 2009-07-02
ZA201004227B (en) 2011-10-26
IL206284A0 (en) 2010-12-30
NI201000110A (es) 2012-05-14
PE20091157A1 (es) 2009-09-03
CL2008003846A1 (es) 2010-02-05

Similar Documents

Publication Publication Date Title
BRPI0811712A2 (pt) "composto, processo de preparação de um composto e composição farmacéutica".
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0812054A2 (pt) Processo para preparar compostos, e, compostos.
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0611956A2 (pt) composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
BRPI0807807A2 (pt) " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ".
BRPI0909691A8 (pt) composto, método para preparar um composto, e, composição farmacêutica
BRPI0814611A2 (pt) Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0911898A2 (pt) processo para preparar compostos, e, composto.
BRPI0815783A2 (pt) Processo para a preparação de 1,2-propanodiol.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0812084A2 (pt) Composto de piperazina, composição, e, processo para combater vegetação indesejada
BRPI0814980A2 (pt) Processo para produzir um composto, e, composto.
BRPI0720530A2 (pt) Partícula, processo para preparar a partícular, e, composição
BRPI1011888A2 (pt) processo para preparar um composto, e, composição.
BRPI0911897A2 (pt) Processo para a preparação de compostos, e, composto
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0905847A2 (pt) "composição farmacêutica injetável e processo para preparar a composição"
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0815784A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0813772A2 (pt) Composto, processo para a preparação de um composto, e, conjugado
BRPI0908738A2 (pt) composto, medicamento, uso de um composto, e, processo para preparar os compostos
BRPI0819568A2 (pt) métodos para a preparação de um composto
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.